secwatch.observer — SEC 8-K summary
======================================

Issuer:     OCTAVE SPECIALTY GROUP INC (OSG)
CIK:        0000874501
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0000874501-25-000131
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ambac Q2 total revenue up 8% to $55M; net loss widens to $72.7M as legacy sale nears approval
--------------------------------------------------------------------------------

- Total P&C premium production surged 110% to $346M, boosted by Beat acquisition.
- Cirrata revenue up 148% to $33M; adjusted EBITDA to shareholders rose 28% to $3M.
- Everspan combined ratio improved to 107% (down 270 bps) on lower loss ratio of 67.8%.
- Net loss from continuing ops to Ambac shareholders $(20.5M) vs $(14.9M) a year ago; adjusted EPS $(0.22).
- Wisconsin OCI recommends approval for AAC sale; hearing set Sept 3, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874501/000087450125000131/0000874501-25-000131-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874501/000087450125000131/ambc-20250807.htm
  HTML page:      https://secwatch.observer/filing/0000874501-25-000131

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer